Prognostic impact of a suboptimal number of analyzed metaphases in normal karyotype lower-risk MDS

Article English OPEN
de Swart, Louise; Smith, Alexandra Gwen; Haase, Detlef; Fenaux, Pierre; Symeonidis, Argiris; Cermak, Jaroslav; Sanz, Guillermo; Stauder, Reinhard; Mittelman, Moshe; Hellström-Lindberg, Eva; Malcovati, Luca; Langemeijer, Saskia; Skov Holm, Mette; Mądry, Krzysztof; Germing, Ulrich; Almeida, Antonio Medina; Tatic, Aurelia; Savic, Aleksandar; Šimec, Njetočka Gredelj; van Marrewijk, Corine; Guerci-Bresler, Agnes; Sanhes, Laurence; Luño, Elisa; Culligan, Dominic; Beyne-Rauzy, Odile; Burgstaller, Sonja; Blijlevens, Nicole; Bowen, David; de Witte, Theo;

Conventional karyotype is one of the most relevant prognostic factors in MDS. However, about 50% of patients with MDS have a normal karyotype. Usually, 20-25 normal metaphases (nMP) are considered to be optimal to exclude small abnormal clones which might be associated ... View more
  • References (13)
    13 references, page 1 of 2

    [1] L. Malcovati, E. Hellstrom-Lindberg, D. Bowen, L. Ades, J. Cermak, C. Del Canizo, M.G. Della Porta, P. Fenaux, N. Gattermann, U. Germing, J.H. Jansen, M. Mittelman, G. Mufti, U. Platzbecker, G.F. Sanz, D. Selleslag, M. Skov-Holm, R. Stauder, A. Symeonidis, A.A. van de Loosdrecht, T. de Witte, M. Cazzola, N. European Leukemia, Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet, Blood 122 (17) (2013) 2943-2964.

    [2] C. Steidl, R. Steffens, W. Gassmann, B. Hildebrandt, R. Hilgers, U. Germing, L. Trumper, D. Haase, Adequate cytogenetic examination in myelodysplastic syndromes: analysis of 529 patients, Leuk. Res. 29 (9) (2005) 987-993.

    [3] P.L. Greenberg, E. Attar, J.M. Bennett, C.D. Bloomfield, U. Borate, C.M. De Castro, H.J. Deeg, O. Frankfurt, K. Gaensler, G. Garcia-Manero, S.D. Gore, D. Head, R. Komrokji, L.J. Maness, M. Millenson, M.R. O'Donnell, P.J. Shami, B.L. Stein, R.M. Stone, J.E. Thompson, P. Westervelt, B. Wheeler, D.A. Shead, M. Naganuma, Myelodysplastic syndromes: clinical practice guidelines in oncology, J. Natl. Compr. Canc. Netw. 11 (7) (2013) 838-874.

    [4] G.M. Rigolin, R. Bigoni, R. Milani, F. Cavazzini, M.G. Roberti, A. Bardi, P. Agostini, M. Della Porta, A. Tieghi, N. Piva, A. Cuneo, G. Castoldi, Clinical importance of interphase cytogenetics detecting occult chromosome lesions in myelodysplastic syndromes with normal karyotype, Leukemia 15 (12) (2001) 1841-1847.

    [5] A. de Swart, T.W. Smith, D. Johnston, J. Haase, P. Droste, A. Fenaux, G. Symeonidis, E. Sanz, J. Hellstrom-Lindberg, U. Cermak, R. Germing, O. Stauder, M. Georgescu, L. MacKenzie, M.S. Malcovati, A.M. Holm, K. Almeida, B. Madry, A. Slama, L. Guerci-Bresler, O. Sanhes, E. Beyne-Rauzy, D. Luno, T. Bowen, Validation of the revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry, Br. J. Haematol. 170 (3) (2015) 372-383.

    [6] J.M. Bennett, World Health Organization classification of the acute leukemias and myelodysplastic syndrome, Int. J. Hematol. 72 (2) (2000) 131-133.

    [7] P. Greenberg, C. Cox, M.M. LeBeau, P. Fenaux, P. Morel, G. Sanz, M. Sanz, T. Vallespi, T. Hamblin, D. Oscier, K. Ohyashiki, K. Toyama, C. Aul, G. Mufti, J. Bennett, International scoring system for evaluating prognosis in myelodysplastic syndromes, Blood 89 (6) (1997) 2079-2088 (1997/3/15).

    [8] P.L. Greenberg, H. Tuechler, J. Schanz, G. Sanz, G. Garcia-Manero, F. Sole, J.M. Bennett, D. Bowen, P. Fenaux, F. Dreyfus, H. Kantarjian, A. Kuendgen, A. Levis, L. Malcovati, M. Cazzola, J. Cermak, C. Fonatsch, M.M. Le Beau, M.L. Slovak, O. Krieger, M. Luebbert, J. Maciejewski, S.M. Magalhaes, Y. Miyazaki, M. Pfeilstocker, M. Sekeres, W.R. Sperr, R. Stauder, S. Tauro, P. Valent, T. Vallespi, A.A. van de Loosdrecht, U. Germing, D. Haase, Revised international prognostic scoring system for myelodysplastic syndromes, Blood 120 (12) (2012) 2454-2465.

    [9] M. Mallo, E. Luno, C. Sanzo, J. Cervera, D. Haase, J. Schanz, G. Garcia-Manero, C. del Canizo, G.F. Sanz, F. Sole, Clinical impact of the clone size in MDS cases with monosomy 7 or 7q deletion, trisomy 8, 20q deletion and loss of Y chromosome, Leuk. Res. 35 (6) (2011) 834-836.

    [10] J. Schanz, H. Tuchler, F. Sole, M. Mallo, E. Luno, J. Cervera, I. Granada, B. Hildebrandt, M.L. Slovak, K. Ohyashiki, C. Steidl, C. Fonatsch, M. Pfeilstocker, T. Nosslinger, P. Valent, A. Giagounidis, C. Aul, M. Lubbert, R. Stauder, O. Krieger, G. Garcia-Manero, S. Faderl, S. Pierce, M.M. Le Beau, J.M. Bennett, P. Greenberg, U. Germing, D. Haase, New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge, J. Clin. Oncol. 30 (8) (2012) 820-829.

  • Similar Research Results (2)
  • Metrics
Share - Bookmark